Personalized oncology care now available through innovative simulation app

Personalized oncology care now available through innovative simulation app

In a groundbreaking development, the CancerMate simulation app is transforming the way doctors approach nonmetastatic triple-negative breast cancer (TNBC) treatment. With the help of COMSOL Multiphysics software, this innovative tool models and simulates TNBC behaviour and treatment outcomes with remarkable precision and accessibility.

CancerMate takes patient-specific data into account, integrating factors such as metabolic tumor volume, tumor-infiltrating lymphocytes (TILs), protein Ki67, total observation period, patient mass, body surface area, dosage, and creatinine levels. This personalized approach allows for more informed decision-making in the clinical setting.

At its core, CancerMate applies biomarkers discovered from a clinical experiment to a set of equations that describe tumor growth and response to treatment over time. A mathematical model was built to predict the metabolic response of breast cancer, virtualize tumor progression, and predict tumor dynamics in response to therapy for individual patients.

Gianpaolo Ruocco, CEO of iBMB Srls, highlights the benefits of CancerMate, stating that it allows doctors to run virtual scenarios, reducing the burden on patients and the cost of treatment. By using COMSOL’s simulation capabilities, researchers can accelerate iterative testing and optimization of treatment strategies for TNBC virtually, reducing reliance on costly and time-consuming physical experiments.

The key contributions of COMSOL Multiphysics in this context include multiphysics modeling, custom simulation apps, and accelerating innovation. COMSOL provides an integrated environment to model interactions between biological, chemical, and physical phenomena simultaneously, such as tumor growth dynamics, drug delivery mechanisms, and tissue interactions relevant to TNBC. This allows the app to deliver personalized simulation results that can assist clinicians and researchers in making more informed decisions without requiring them to operate complex simulation software directly.

CancerMate's user-friendly interface includes input fields for patient-specific data and displays numerical results for predicted clinical lesion values and a graphic showing the progress of the predicted cancer lesion volume and integrated drug concentration. The app was validated against data from a clinical experiment conducted with patients treated with LYNPARZA® for nonmetastatic TNBC, and is currently ready for implementation in a clinical setting for TNBC treated with LYNPARZA®.

Ruocco also mentioned that the app's underlying technology could be trained to cover more breast cancer subtype-therapy pairings and extended to other types of cancer and drug products. The results from CancerMate can help oncologists monitor solid tumor progression and adjust therapeutic strategies accordingly. With CancerMate, clinicians can assess and monitor tumor lesion volumes, potentially modifying treatment duration with in silico tools.

In summary, CancerMate is a game-changer in personalized oncology, leveraging the power of COMSOL Multiphysics to model and simulate TNBC behavior and treatment outcomes. This app's user-friendliness and simulation capabilities make it invaluable in personalized cancer treatment for oncologists and pharmaceutical researchers.

1. The CancerMate simulation app, designed for nonmetastatic triple-negative breast cancer (TNBC) treatment, uses patient-specific data in its personalized approach.
2. CancerMate employs AI-driven analytics, integrating factors like metabolic tumor volume, TILs, protein Ki67, total observation period, patient mass, body surface area, dosage, and creatinine levels.
3. Researchers can utilize this app to run virtual scenarios, aiding in informed decision-making in the medical-conditions domain, while reducing patient burden and treatment costs.
4. The medtech sector has benefited from COMSOL Multiphysics, enabling a multi-physics modeling environment for biological, chemical, and physical phenomena interactions, such as tumor growth dynamics, drug delivery mechanisms, and tissue interactions relevant to TNBC.
5. In the realm of health-and-wellness and data-and-cloud-computing, CancerMate's technology could be extended to cover more breast cancer subtype-therapy pairings, other types of cancer, and drug products.
6. This innovative app equips oncologists with an in silico tool, allowing them to monitor solid tumor progression, adjust therapeutic strategies, and assess tumor lesion volumes, contributing to the advancement of personalized oncology treatment.

Read also: